



Express Mail Label No.: EV538965388US
Date of Deposit: August 31, 2006

Attorney Docket No. 33743-501CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Michael P. Bevilacqua et al.
SERIAL NUMBER : 10/781,558 EXAMINER : Zeman, Mary K.
FILING DATE : February 17, 2004 ART UNIT : 1631
FOR : SYSTEMS AND METHODS FOR CHARACTERIZING A BIOLOGICAL CONDITION OR
AGENT USING PRECISION GENE EXPRESSION PROFILES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified application are the following documents:

1. Revocation by Assignee and New Power of Attorney (2 pgs);
2. Schedule A (2 pgs); and
3. Return postcard.

The Commissioner is hereby authorized to charge any fee that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Reference No. 33743-501CIP2. A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: August 31, 2006

Express Mail Label No.: EV538965388US

Date of Deposit: August 31, 2006

Attorney Docket No. 33743-501 CIP2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSIGNEE: Source MDX
SERIAL NUMBER: See Attached Schedule A
FILING DATE: See Attached Schedule A
FOR: See Attached Schedule A

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

Source Precision Medicine, Inc. d/b/a Source MDX, a company and owner ("Assignee") of the patents and patent applications listed on the attached Schedule A, hereby revokes any and all former powers of attorney and hereby appoints the attorneys and/or agents associated with Mintz Levin Cohn Ferris Glovsky & Popeo, Customer Number 30623, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the patent application.

Please address all telephone calls to Ivor R. Elrifi at telephone number 617/348-1747.
Please address all correspondence to Customer No. 30623.

The undersigned is authorized to act on behalf of the Assignee in the above-referenced patent application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Karl Wassmann', written over a horizontal line.

NAME: KARL WASSMANN

TITLE: CEO & PRESIDENT

COMPANY: SOURCE PRECISION MEDICINE, INC
D/B/A SOURCE MDX

Date: 7/20/06

TRA 2172070v.1



Schedule A

U.S. APPLICATIONS

Docket No.	Title	Serial No.	Filing or 371(c) Date	Assignment
33743-501	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/742,458	19-Dec-2003	Reel 014814 Frame 0980
33743-501 CIP2	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/781,558	17-Feb.-2004	Reel 014841 Frame 0216
33743-502	Quantitative Assay for Low Abundance Molecules	09/595,720	16-June- 2000	Reel 011174 Frame 0646
33743-503	Systems and Method for Characterizing a Biological Condition or Agent Using Calibrated Gene Expression Profiles	09/605,581	28-June-2000	Reel 011547 Frame 0141
33743-503 CIP	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	09/821,850	29-Mar-2001	Reel 015766 Frame 0994
33743-503 CIP2	Identification of Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles	10/291,225	8-Nov-2002	Reel 014068 Frame 0793
33743-503 CIP DIV	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/703,143	03-Nov-2003	Reel 014816 Frame 0001

33743-503 CIP DIV 2	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/701,391	03-Nov-2003	Reel 014825 Frame 0601
33743-503 CIP DIV 3	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/772,783	05-Feb-2004	Reel 014916 Frame 0953
33743-503 CIP DIV 4	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/778,594	13-Feb-2004	Reel 014840 Frame 0754
33743-503 CIP DIV 5	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/778,597	16-Feb-2004	Reel 015582 Frame 0332
33743-503 CIP DIV 6	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/778,603	16-Feb-2004	Reel 015560 Frame 0870
33743-503 CIP DIV 7	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/778,679	16-Feb-2004	Reel 015565 Frame 0852
33743-504	Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles	10/291,856	08-Nov-2002	Reel 015624 Frame 0757
33743-504CON	Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles	11/158,504	22-June-2005	Reel 015624 Frame 0757
33743-504CON2	Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles	11/159,376	22-June-2005	Reel 015624 Frame 0850
33743-504CIP	Gene Expression Profiling for Identification Monitoring and Treatment of Multiple Sclerosis	11/155,930	16-June-2005	Reel 017072 Frame 0447